QUICK SPARK: Russell 2000 Hits New Record Highs, Beats Nasdaq 100 In 2026
The Russell 2000 hits a record high as small caps outperform the Nasdaq 100, led by three companies, including AN2 Therapeutics.
Read original at benzingaStocks · News reference
Guggenheim Initiates Coverage On AN2 Therapeutics with Buy Rating, Announces Price Target of $9
Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Buy rating and announces Price Target of $9.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 12:03 PM
- Checked
- Jul 20, 2026, 12:03 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
AN2 Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Read original at benzingaAN2 Therapeutics Q2 EPS $(0.18) Beats $(0.27) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 14.29 percent increase over losses of $(0.21) per share from
Read original at benzinga